SCHEMBL18188218

SCHEMBL18188218

CC(F)C(=O)Nc1ccc(C(F)(F)F)nc1Nc1ccc2[nH]ncc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 7/20 0.46
▸ ROCK1 Q13464 6/20 0.46
▸ NPC1 O15118 4/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ SYK P43405 2/20 0.44
▸ JAK2 O60674 1/20 0.43
▸ MAP4K4 O95819 2/20 0.42
▸ RPS6KB1 P23443 2/20 0.42
▸ CLK2 P49760 2/20 0.42
▸ DYRK1A Q13627 2/20 0.42
▸ CLK4 Q9HAZ1 2/20 0.42
▸ DYRK3 O43781 1/20 0.42
▸ CSNK2A1 P68400 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ PRKG1 Q13976 1/20 0.42
▸ PRKD2 Q9BZL6 1/20 0.42
▸ SGK2 Q9HBY8 1/20 0.42
▸ STK17A Q9UEE5 1/20 0.42
▸ HSF1 Q00613 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18188414 0.82 NPC1 (0.52) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL18188230 0.82 NPC1 (0.43) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL30272857 0.76 SYK (0.46) ROCK2ROCK1NPC1RAB9ASYK
SCHEMBL29542975 0.75 MKNK1 (0.53) ROCK2ROCK1RAB9AHSF1MKNK1
SCHEMBL18188436 0.75 MKNK1 (0.53) ROCK2ROCK1RAB9AHSF1MKNK1
SCHEMBL28597254 0.71 ROCK2 (0.43) ROCK2ROCK1NPC1RAB9AHSF1
SCHEMBL30272874 0.70 SYK (0.47) ROCK2ROCK1SYKJAK2MAP4K4
SCHEMBL19699462 0.70 ROCK2 (0.71) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL16834423 0.68 NPC1 (0.60) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL13730011 0.68 TRPV1 (0.46) NPC1RAB9ASYKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 — — US disclosed
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators RAPPORT THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-19 — — US disclosed
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-12 — — US disclosed
US-20230110576-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-04-13 — — US disclosed
US-20230114165-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-04-13 — — US disclosed
EP-4144736-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-03-08 — — EP disclosed
US-11312712-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2022-04-26 — — US disclosed
EP-3901153-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2021-10-27 — — EP disclosed
US-20210284641-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-16 — — US disclosed
CN-107835814-B Azabenzimidazoles and their use as AMPA receptor modulators 詹森药业有限公司 2021-07-23 — — CN disclosed
EP-3288940-B9 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 — — EP disclosed
EP-3288940-B1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-24 — — EP disclosed
US-20180118740-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
EP-3288940-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP disclosed
WO-2016176460-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284641-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-20180118740-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-20230110576-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-11312712-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-20230114165-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A ROCK2 4289/4885ROCK1 4034/4885NPC1 2055/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A ROCK2 4282/4885ROCK1 3993/4885NPC1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback